Graft-Specific Regulatory T Cells for Long-Lasting, Local Tolerance Induction
Authors:
- Nadja SeltrechtNSNadja Seltrecht
- Matthias Hardtke-WolenskiMatthias Hardtke-Wolenski
- Konstantinos IordanidisKIKonstantinos Iordanidis
- Danny JonigkDJDanny Jonigk
- Melanie GallaMGMelanie Galla
- Axel SchambachAxel Schambach
- Laura Elisa Buitrago-MolinaLBLaura Elisa Buitrago-Molina
- Heiner WedemeyerHWHeiner Wedemeyer
- Fatih NoyanFNFatih Noyan
- Elmar JaeckelEJElmar Jaeckel
Open Access
Abstract
Background: Solid organ transplantation is hindered by immune-mediated chronic graft dysfunction and the side effects of immunosuppressive therapy. Regulatory T cells (Tregs) are crucial for modulating immune responses post-transplantation; however, the transfer of polyspecific Tregs alone is insufficient to induce allotolerance in rodent models. Methods: To enhance the efficacy of adoptive Treg therapy, we investigated different immune interventions in the recipients. By utilizing an immunogenic skin transplant model and existing transplantation medicine reagents, we facilitated the clinical translation of our findings. Specifically, antigen-specific Tregs were used. Results: Our study demonstrated that combining the available induction therapies with drug-induced T-cell proliferation due to lymphopenia effectively increased the Treg/T effector ratios. This results in significant Treg accumulation within the graft, leading to long-term tolerance after the transfer of antigen-specific Tregs. Importantly, all the animals achieved operational tolerance, which boosted the presence of adoptively transferred Tregs within the graft. Conclusions: This protocol offers a means to establish tolerance by utilizing antigen-specific Tregs. These results have promising implications for future trials involving adoptive Treg therapy in organ transplantation.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (SFB738 (Project B4), TRR127 (Project A4), NFRF-2020-00787)
- zukunft.niedersachsen (SFB738 (Project B4), TRR127 (Project A4), NFRF-2020-00787)
- Government of Canada’s New Frontiers in Research Fund (NFRF) (SFB738 (Project B4), TRR127 (Project A4), NFRF-2020-00787)
This publication has 57 references indexed in Scilit:
- Immunosuppression Withdrawal in Liver Transplant Recipients on SirolimusHepatology, 2020
- Human‐engineered Treg‐like cells suppress FOXP3‐deficient T cells but preserve adaptive immune responses in vivoClinical & Translational Immunology, 2020
- Restoring self-tolerance in autoimmune diseases by enhancing regulatory T-cellsCellular Immunology, 2019
- Human FOXP3+ Regulatory T Cell Heterogeneity and Function in Autoimmunity and CancerImmunity, 2019
- Generation of human islet-specific regulatory T cells by TCR gene transferJournal of Autoimmunity, 2017
- A pilot study of operational tolerance with a regulatory T‐cell‐based cell therapy in living donor liver transplantationHepatology, 2016
- Autoimmune hepatitis in a murine autoimmune polyendocrine syndrome type 1 model is directed against multiple autoantigensHepatology, 2014
- Isolation of human antigen‐specific regulatory T cells with high suppressive functionEuropean Journal of Immunology, 2014
- Plasticity of Foxp3+ T Cells Reflects Promiscuous Foxp3 Expression in Conventional T Cells but Not Reprogramming of Regulatory T CellsImmunity, 2012
- Loss of FOXP3 expression in natural human CD4+CD25+ regulatory T cells upon repetitive in vitro stimulationEuropean Journal of Immunology, 2009